Deciphering Hepatic Host Transcriptomic Responses to Leishmania Infection: Integrating Evidence from In Vivo and In Vitro Studies
Abstract
Visceral leishmaniasis (VL) is a life-threatening, vector-borne systemic disease caused by the parasitic protozoans Leishmania donovani and Leishmania infantum. Among the affected organs, the liver represents a unique immunological environment in which, in commonly used experimental murine models, infection is often controlled through the coordinated formation of granulomas around infected Kupffer cells. However, effective hepatic parasite control does not necessarily result in complete parasite elimination, and the course of infection may vary across host species and experimental models. Understanding the molecular mechanisms governing parasite clearance and persistence has been greatly advanced by transcriptomic technologies. The transition from bulk RNA sequencing to single-cell RNA sequencing and, more recently, spatial transcriptomics has enabled increasingly detailed characterization of hepatic immune responses, revealing cellular heterogeneity, spatial organization, and regulatory networks underlying host–parasite interactions. In parallel, the development of advanced in vitro models, including multicellular co-cultures and organoid-based systems, has provided complementary platforms for investigating these mechanisms under controlled experimental conditions. This review provides an integrated analysis of transcriptomic studies investigating hepatic host responses to Leishmania infection across different experimental models and transcriptomic approaches. We examine the molecular pathways underlying host defense, granuloma formation, and parasite persistence, compare the complementary insights provided by distinct transcriptomic approaches, and critically evaluate the extent to which in vitro models reproduce the hepatic transcriptional landscape observed in vivo. By integrating findings across experimental platforms and transcriptomic resolutions, we identify conserved immune signatures, model-specific limitations, and key biological and technological knowledge gaps that should guide the development of more physiologically relevant experimental models and future transcriptomic studies of the liver during VL.